Antisense therapeutics: from theory to clinical practice.

摘要: The use of antisense (AS) oligonucleotides as therapeutic agents was proposed far back the 1960s/1970s when AS strategy initially developed. However, it has taken almost a quarter century for this potential to be realized. last few years seen rapid increase in number molecules progressing past Phase I clinical trials, due part our increased knowledge their structure and chemistry. Here, we describe most prominent these modifications with respect applicability. main focus review is application, on cancer. We will discuss detail both status current trials that are likely targets next group entering clinic.